drugset / Trial / NCT05427747
Meropenem vs Cefotaxime as Empirical Treatment of SBP
RandomizedParallel-groupDouble-blindTreatment
Summary
We aimed to evaluate whether meropenem is superior to cefotaxime for treatment of SBP empirically.
Timeline
- Start
- 2023-01-01
- Primary completion
- 2024-01
- Completion
- 2024-02
Publications
- Results Finci L, Mouraux S, Knuchel J, Bochatay L. [Initial management of new onset ascites in patient with cirrhosis]. Rev Med Suisse. 2017 Sep 6;13(573):1509-1515. French.
- Results Sarwar S, Tarique S, Waris U, Khan AA. Cephalosporin resistance in community acquired spontaneous bacterial peritonitis. Pak J Med Sci. 2019 Jan-Feb;35(1):4-9. doi: 10.12669/pjms.35.1.17.
- Results Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut. 2012 Feb;61(2):297-310. doi: 10.1136/gutjnl-2011-300779. Epub 2011 Dec 6. No abstract available.
- Results Ameer MA, Foris LA, Mandiga P, Haseeb M. Spontaneous Bacterial Peritonitis(Archived). 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK448208/
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cefotaxime | Small molecule | 2 g | Intravenous |
| Subject | Meropenem | Small molecule | 1 g | Intravenous |